Apellis Pharma has become the first company to claim FDA approval for a drug to treat geographic atrophy (GA), a sight ... and retinal pigment epithelial (RPE) cells, the central portion of ...

to commence human trials for Eyecyte RPE. According to the company’s press statement, the therapy is aimed at combating geographic atrophy arising from dry age-related macular degeneration (AMD).

Serpiginous chorioretinopathy is a rare form of posterior uveitis that causes inflammation and subsequent atrophy of the choroid, RPE and retina. The disease typically starts near the optic nerve ...

The phase 1b trial will enrol patients with geographic atrophy secondary to age-related ... of photoreceptors and retinal pigment epithelial (RPE) cells in the central portion of the retina ...